Status:
COMPLETED
Study of Tarceva and Targretin in Stage I-II Lung Cancer
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborating Sponsors:
Ligand Pharmaceuticals
Genentech, Inc.
Conditions:
Carcinoma, Non-small-cell Lung
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and D...
Detailed Description
Erlotinib 150mg and bexarotene 400mg/m2 will be administered orally for 7-9 days prior to thoracotomy. Plasma samples will be collected on the day before surgery and along with tissue samples on the d...
Eligibility Criteria
Inclusion
- Resectable stage I or II non-small-cell lung cancer
- Prior tissue biopsy (not cytology) available for research analysis
- Adequate hepatic and renal function
Exclusion
- Prior chemotherapy or radiotherapy
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00125372
Start Date
December 1 2005
End Date
August 1 2010
Last Update
January 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States, 03756